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Abstract 
A single nucleotide transversion (G + C) in the 5’ donor site of intron 7 of the P-hexosaminidase a-chain gene was identified in two 
Portuguese patients with infantile Tay-Sachs disease. One patient was found to be homozygous and the other a compound heterozygote 
with the four-base insertion in exon 11 on the other allele. In fibroblasts from the homozygous patient the /3-hexosaminidase (Y mRNA 
was observed as a nearly undetectable fast migrating band. Through cDNA-PCR amplification and hybridization with full length (Y 
cDNA several fragments of smaller size than the normal transcript were detected, most of them lacking exon 7. We propose that this point 
mutation in the 5’ donor site of intron 7 of the P-hexosaminidase a-chain gene is responsible for an inefficient and abnormal processing 
of the mutant transcript, resulting in functional abnormality. 
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1. Introduction 
GM2-Gangliosidosis is a group of recessively inherited 
neurodegenerative disorders, characterized by lysosomal 
accumulation of GM2 ganglioside. Three glycoproteins are 
essential for in vivo degradation of GM2 ganglioside - 
P-N-acetyl-D-hexosaminidase (EC 3.2.1.52) (Y and P-sub- 
units and the GM2 activator protein - each encoded by a 
distinct gene. Abnormalities in these genes lead respec- 
tively to variant B, variant 0 and variant AB. Genetic 
defects in the a-subunit result in loss of P-hexosaminidase 
A ((Y/I heterodimer) activity, and that of P-subunit abol- 
ishes activities both isoenzymes, &hexosaminidase A and 
B (homodimer /3p) [l]. The classic infantile form of the 
genetic @hexosaminidase (Y chain defects is Tay-Sachs 
disease that occurs at a high frequency among Ashkenazi 
Jews. This disease is rapidly progressive and fatal. Two 
mutations, a splicing defect at the 5’ donor site of intron 12 
and a 4-base insertion within exon 11, account for almost 
all cases of classic infantile Ashkenazi Tay-Sachs disease 
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[2-61. A clinically typical but genetically distinct infantile 
form of (Y subunit defect, occurring among French- 
Canadian population, was found to be due to a major 
deletion at the 5’ end of the P-hexosaminidase (Y chain 
gene [7,8]. In both the infantile Ashkenazi Jewish and the 
French Canadian forms, no or little detectable mRNA or 
enzyme protein is produced. Besides these ethnically re- 
stricted forms, many distinct abnormalities underlaying 
defective a-subunit have been described but they occur 
panethnically at lower frequencies. In some forms of the 
disease such as the enzymologically unique Bl variant, an 
immunologically detectable but catalytically defective en- 
zyme protein is produced. The first and more frequent 
mutation in the a-subunit associated to Bl variant pheno- 
type was the G-533 --, A transition in exon 5 (DN-allele), 
translating into arginine-histidine substitution at residue 
178 [9]. Three other point mutations causing the Bl pheno- 
type have been reported, C-532 -+ T in exon 5 [lo], G-772 
-+ C in exon 7 [ll] and G-574 + C in exon 6 [12]. This 
rare disorder, with a wide ethnic and geographic distribu- 
tion, is the most frequent form of GM2 Gangliosidosis in 
Portugal [13]. Among Portuguese patients with genetic 
defects in the a-subunit, the ‘DN-allele’ represents 77% of 
the mutant alleles. 
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In the present study we report the presence of a muta- 
tion at + 1 position of intron 7 splice site of P-hexosa- 
minidase a chain gene in two Portuguese unrelated pa- 
tients with the infantile phenotype of Tay-Sachs disease. 
Its implication on transcription and translation is further 
evaluated. 
2. Materials and methods 
2.1. Clinical description 
We studied two unrelated patients. Both had the onset 
of the disease around 6 months of age. Patient 1, when 
examined at 13 months of age, was a floppy baby and in 
spite of a marked hypotonia, her upper limbs were in a 
pronation position and pyramidal signs were present. There 
was a marked startle reaction to various stimuli. Cherry red 
spot was seen in fundi. Her parents are related as third 
cousins. Patient 2, when seen at 14 months of age, was 
unable to sit and to control her head. Acoustic startle was 
prominent even with minimal stimuli. She was a very 
hypotonic child with brisk reflexes and bilateral Babinski 
sign. Generalised tonic-clonic seizure was also observed. 
Optic fundi showed bilateral cherry red spot. 
2.2. Commercial materials 
4-Methylumbelliferyl-N-acetylglucosamine (4-MU- 
GlcNAc) was purchased from Sigma and its sulfated 
derivative (4-MU-GlcNAc-6-S) from Moscerdam (The 
Netherlands). The commercial preparation of the sulfated 
substrate was purified by chromatographic procedures as 
described by Beccari et al. [14]. DE-52 cellulose was 
obtained from Whatman Biosystems, Cellogel strips from 
Chemetron and bovine serum albumin (BSA) from Sigma. 
[-y-3’ P]dATP ( > 5000 Ci/mmol), [ (Y-~~P]~ATP ( > 1000 
Ci/mmol) and [ a-32P]dCTP ( > 3000 Ci/mmol) were 
purchased from Amersham. T4 polynucleotide kinase was 
purchased from New England Biolabs. Sources for non- 
standard materials will be indicated below as appropriate. 
2.3. Biological materials 
Leucocytes were isolated from peripheral blood. Leuco- 
cyte-pellets were extracted by brief sonication in 0.1% 
(v/v> Triton X-100. After centrifugation for 30 min at 
15 000 X g the supematant (reffered to as extract) was 
assayed for enzyme activities. Epstein-Barr Virus (EBV)- 
transformed lymphoblast cell lines were established as 
described [15]. Skin fibroblasts were grown and propa- 
gated in RPM1 medium supplemented with antibiotics and 
5% FCS at 37°C in 5% CO,. From patient 2 no biological 
material was available and therefore only her parents could 
be studied. 
2.4. Enzymatic assays 
The /?-hexosaminidase activity was determined against 
the synthetic neutral (4-MU-GlcNAc) and sulfated (4- 
MU-GlcNAc-6-S) substrates, based on the assay condi- 
tions previously described [16,17]. Total extracts were 
incubated with 4-MU-GlcNAc (1.7 mM final concentra- 
tion) in 0.1 M citrate phosphate buffer pH 4.4 at 37°C for 
15 min or with 4-MU-GlcNAc-6-S (1.0 mM final concen- 
tration) in 0.2 M citrate phosphate buffer pH 4.0 at 37°C 
for 1 h. The reactions were stopped by the addition of 1.0 
ml of 1 M of glycine-NaOH pH 10.0 and the fluorescence 
measured on a Aminco SPR spectrofluorometer with an 
excitation and emission wavelengths of 366 and 446 nm, 
respectively. Protein was determined according to Lowry 
et al. [18] using BSA as standard. 
2.5. Cellulose acetate gel electrophoresis 
Cellulose acetate gel electrophoresis of P-hexosamini- 
dase was performed on Cellogel strips (5.7 cm X 14.0 cm) 
as previously described [19]. After electrophoresis p- 
hexosaminidase activity was detected by incubation at 
37°C with 4-MU-GlcNAc, 2.0 mM in 0.1 M citrate phos- 
phate buffer pH 4.75 for 10 min or with 4-MU-GlcNAc-6- 
S, 2.0 mM in 0.1 M citrate phosphate buffer pH 4.0 for 45 
min. The fluorescence was developed with 1 M glycine- 
NaOH, pH 10.0, visualized at 366 nm and photographed 
with type 667 Polaroid film. 
2.6. DEAE-cellulose chromatography 
Sonicated extracts containing equal amounts of protein 
were applied to 1 ml DE-52 column equilibrated with 10 
mM sodium phosphate buffer and 0.6 ml fractions were 
collected. After unretained P-hexosaminidase B has been 
eluted, the remaining isoenzymes were separated using a 
linear NaCl gradient (0 to 0.35 M in 15 ml of the column 
buffer). The enzymatic activities of eluted fractions were 
determined against 4-MU-GlcNAc and 4-MU-GlcNAc-6-S. 
2.7. PCR amplification of genomic DNA 
DNA was isolated from lymphoblasts according to the 
standard procedure [20]. Exon 7 and flanking intron se- 
quences of the a-subunit gene were amplified by PCR. 
One primer was within intron 6,48 bases upstream of exon 
7 (5’-GCTAGCTITCAGGAAGTGTGAACC-3’ ) and the 
other was within intron 7, 40 bases downstream of exon 7 
(5’-TAACAAGCAGAGTCCCTCTGGT-3’). Initial denatu- 
ration was at 94°C for 5 min, followed by 30 cycles of 
denaturation at 94°C for 30 s, annealing at 55°C for 30 s 
and extension at 72°C for 1.5 min. 
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Fig. 1. (A) Cellulose acetate gel electrophoretic profile of P-hexosa- 
minidase in leucocyte extracts. After electrophoresis Phexosaminidase 
activity was stained with 4-MU-GlcNAc (I) and 4-MU-GlcNAc-6-S (II). 
P, patient 1; C, control; B, Bhexosaminidase B; A, Phexosaminidase A. 
(B) Ion-exchange chromatographic profile of /3-hexosaminidase present 
in leucocytes. The enzymatic activities were determined against 4-MU- 
GlcNAc and 4-MU-GlcNAc-6-S. * , control, 4-MU-GlcNAc; W, patient 
1, 4-MU-GlcNAc; + , control, 4-MU-GlcNAc-6-S; 0, patient 1, 4-MU- 
GlcNAc-6-S. 
2.8. Direct sequencing of PCR products 
A portion from the first amplification reaction was 
subjected to assymmetric amplification using only the 
antisense primer. The assymmetric PCR products were 
freed from primers, nucleotides and salts using QIAGEN 
kit (Diisseldorf, Germany) according to the manufacturer’s 
procedure. Sequencing of the sense strand was performed 
using Sequenase (version 2.0) kit (US Biochemical) ac- 
cording to the procedure recommended by the mamtfac- 
turer. 
2.9. Restriction enzyme analysis 
About 100-200 ng of the amplified PCR fragment was 
digested overnight at 37°C with 10 units of AluI restric- 
tion enzyme. The restriction fragments were analyzed by 
electrophoresis on a 10% nondenaturing polyacrylamide 
gel. The DNA bands were visualized by staining with 
ethidium bromide. 
2.10. RNA preparation, northern blot analysis and cDNA- 
PCR amplification 
Total RNA was isolated from fibroblast cell lines of 
patient 1 and a control according to the procedure de- 
scribed by Chomczynski and Sacchi [21]. Integrity of total 
RNA was checked by electrophoresis, through the estima- 
tion of 28S/18S ratio. About 25 pg of total RNA were 
electrophoresed in a 1% agarose/formaldehyde denaturing 
gel and transferred to GeneScreen Plus nylon membrane 
(NEN Research Products). Hybridization with the full- 
length normal P-hexosaminidase a-subunit cDNA [22] 
labelled with [ CF~‘P]~CTP were performed using the 
Megaprime’” DNA Labeling System (Amersham) accord- 
ing to the instructions of manufacturer. Blots were exposed 
to Kodak X-ray film at -70°C using DuPont Cronex 
lightning Plus intensifying screen. The Phexosaminidase 
P-subunit cDNA was used as control probe. 
Total RNA was reverse-transcribed into cDNA using 
GeneAmp RNA PCR Kit (Perkin Elmer C&us), according 
to the manufacturer’s procedure with 2 pg of total fibrob- 
last RNA, oligo d(Tj16 as primer and 1.5 h incubation at 
42°C. The amplification of the segment corresponding to 
the entire coding sequence was performed using 40 pmol 
of each forward (S-TCCGAGAGGGGAGACCAGCGG-3' , 
located 24 bp upstream of the A of the initiation codon) 
and reverse (S-TCACCTACAGCCAGCACCCTC-J, lo- 
Table 1 
P-Hexosaminidase activities determined in leucocyte extracts 
4-MU-GlcNAc 4-MU-GlcNAc-6S 
total Hex %HexA Hex A 
Pl 1200 0 3.49 
Mother (Pl) 1070 59.5 122 
Father (Pl) 1090 65.0 140 
Mother (P2) 1712 47.8 155 
Father (P21 1714 55.6 143 
Controls 
mean 1520 87.1 255 
range 967-2294 81.0-91.4 109-380 
Il= 50 10 50 
Total Hex, Phexosaminidase activity (nmol/h per mg protein) deter- 
mined against the neutral synthetic substrate; % Hex A, /3-hexosamini- 
dase A activity as % of total &hexosaminidase recovered after DEAlS- 
cellulose chromatography; Hex A, fi-hexosaminidase A activity (nmol/h 
per mg protein) determined against the sulfated substrate; Mother and 
Father (Pl), parents of patient 1; Mother and Father (P21, parents of 
patient 2. For details see Materials and methods. 
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cated 36 bp downstream of the stop codon) primers and 
the following amplification profile: initial denaturation at 
94°C for 5 min followed by 35 cycles of denaturation at 
94°C for 1 min and annealing/extension at 68°C for 5 
min. 
2.11. Southern analysis 
The cDNA amplified fragments were electrophoresed in 
1.2% agarose gel DNA and transfered to GeneScreen Plus 
nylon membrane (NEN Research Products). Hybridizations 
with full-length normal P-hexosaminidase a-subunit 
cDNA 1221 or normal exon 7 probe (synthesized by PCR 
using oligonucleotides that exactly matched the ends of the 
exon) labelled with [ a-32P]dCTP were performed using 
the Megaprime’” DNA Labeling System (Amersham) ac- 
cording to the instructions of manufacturer. Blots were 
exposed to Kodak X-ray film at -70°C using DuPont 
Cronex lightning Plus intensifying screen. 
2.12. Screening for the infantile Ashkenazi Jewish alleles 
The exon 11 4-bp insertion and intron 12 splicing 
mutation were screened by PCR and allele-specific probes 
under the conditions previously described [lo]. 
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Fig. 3. (A) Northern blot analysis of P-hexosaminidase (Y chain mRNA. 
The Blot was hybridized with full lenght a-subunit cDNA. Lane C, 
Control fibroblasts, 25 pg of total RNA, lane P, patient 1 fibroblasts, 25 
pg of total RNA. (B) Analysis of the cDNA amplified fragments. l/50 
of each PCR reaction was loaded on a 1.2% agarose gel, transferred to 
GeneScreen Plus nylon membrane and hybridized with full-lenght cDNA 
(A) or exon 7 probe (B). The film was deliberately over-exposed (0) in 
order to show the cDNA amplified fragments of abnormal sizes in the 
patient’s sample. They were undetectable when the film was properly 
exposed for the normal sample. The fragment lenght is indicated in base 
pairs. P, patient 1; C, control. 
Sequence analysis of the exon 7/intron 7 boundary region of 
1 (P) and control (0. Sequencing reactions were performed 
on PCR amplification products as described in Materials and 
s. The relevant portion of the sequencing gel is shown. The C 
ed by an arrow) in this patient should be G in normal individuals. 
2.13. Cell labeling, immunoprecipitation and polyacryl- 
amide gel electrophoresis 
Fibroblasts were cultured in 75-cm2 flask and labelled 
with 0.375 mCi [4,5-3H]leucine (65 Ci/mmol). Cells were 
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harvested after 22 h pulse. Subsequent extraction of cellu- 
lar protein, immunoprecipitation with anti-hexosaminidase 
A antiserum, the polyacrylamide gel electrophoresis and 
autoradiography were essentially as described previously 
[231. 
3. Results 
3.1. Biochemical study 
In leucocytes, the residual /3-hexosaminidase A activity 
(4-MU-GlcNAc-6-S) was less than 1.5% in patient 1 and 
about 50-60% of control mean in obligate carriers (Table 
1). Fig. 1A and B show the separation of P-hexosamini- 
dase isoenzymes present in leucocytes from the patient 1 
and a control, respectively by cellulose acetate gel elec- 
trophoresis and ion-exchange chromatography. As can be 
observed, no activity of /3-hexosaminidase A against 4- 
MU-GlcNAc and 4-MU-GlcNAc-6-S was detected in pa- 
tient 1. 
3.2. Molecular study 
Direct sequencing of the PCR-amplified genomic DNA 
from patient 1 showed the G --) C transversion at + 1 
position of intron 7 (Fig. 2). Nucleotide sequence of DNA 
from the parents of patient 2 showed that both the mutant 
cytosine and the normal guanosine were present in the 
latwe 
Fig. 4. Synthesis of &hexosaminidase in fibroblasts. Cells were labeled 
with [3H]leucine for 22 h. Antibody to P-hexosaminidase A was used to 
immunoprecipitate the cell extracts. P, patient 1; C, control. 
mother whereas the father presented the normal sequence 
around the junction of exon 7 and intron 7 (data not 
shown). Thus, the patient 1 was homozygous for the 
G -+ C transversion at position + 1 of intron 7 and the 
patient 2 was concluded to be a compound heterozygote 
with only one allele carrying this mutation. 
The effect of the G + C transversion in 5’ donor site of 
intron 7 on (Y mRNA was firstly analyzed by Northern 
blot of total RNA (Fig. 3A). In contrast to a band of 
expected size observed in control fibroblasts, a nearly 
undetectable band of a smaller size than the normal was 
observed in the patient. Using the appropriate oligonucleo- 
tides the entire coding sequence was reverse transcribed 
and the Q chain cDNA amplified by polymerase chain 
reaction. The length of the amplified product obtained for 
patient 1 was compared with that of the control after 
agarose gel electrophoresis, blotting and hybridization us- 
ing either full-length (Y chain cDNA or exon 7 as probe 
(Fig. 3B). Using the full-length cDNA as the probe, only 
the expected band of 1650 bp was seen in the normal 
control, while multiple bands of varying sizes, mostly 
smaller than the normal 1650 bp, were present in patient 1. 
When exon 7 was the probe, none of the multiple bands in 
the patient’s fibroblasts were detectable when the film was 
exposed for the normal length of time. When over-ex- 
posed, a faint signal was detected for the major, fast- 
migrating band. Thus, most of the amplified fragments 
from patient 1 fibroblasts lack exon 7. The faster-migrating 
band detectable in the Northern blotting (Fig. 3A) can be 
interpreted from its size and lack exon 7 as an (Y subunit 
mRNA lacking exon 7 but otherwise normal (1517 bp). 
When cultured firoblasts were labeled with tritiated 
leucine for 22 h, the mature (Y subunit form were not 
detected (Fig. 4). 
The G + C transversion in the 5’ end splicing site of 
intron 7 creates an AZuI (5’-AGCT-3’) restriction site as 
well as it abolishes the restriction sites for EcoRII and 
ScrFI. Since the last two restriction enzymes are used in 
the diagnosis of Gly-269 mutation, the detection of this 
splicing mutation can be carried out through the amplifica- 
tion of the exon 7/intron 7 boundary region of genomic 
DNA followed by the digestion of the resulting fragment 
with AluI. The products of the digestion can be examined 
by electrophoresis on a polyacrylamide gel. The principle 
of this assay is shown schematically in Fig. 5 (bottom). 
The digestion yelds a 216 bp from the normal allele or 176 
bp and 40 bp fragments from the mutant allele. The 
enzyme also produces an undetectable 5 bp fragment from 
both alleles. As it can be observed in the Fig. 5 (top), the 
restriction enzyme assay showed in patient 1 both 176 bp 
and 40 bp fragments and in her parents the three fragments 
of 216 bp, 176 bp and 40 bp, as expected for hetero- 
zygotes. In the mother of patient 2 the three fragments 
were also present, whereas in her father only the 216 bp 
fragment was detected. These results corroborated the 
sequencing data. 
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Fig. 5. (Top) Diagram showing the strategy for screening the mutant allele. (Bottom) Detection of G + C transversion at the position + 1 of intron 7 of 
P-hexosaminidase a-subunit gene. The PCR-amplified fragment was digested with Alu I restriction enzyme and the samples electrophoresed on 10% 
polyacrylamide gel. Lane M, molecular weight markers (pBr 322 DNA/MspI digest); lane 1, normal control; lane 2, patient 1; lane 3, patient l’s father; 
lane 4, patient l’s mother; lane 5, patient 2’s father; lane 6, patient 2’s mother. 
The DNA from both parents of patient 2 was tested for 
the presence of exon 11 4 bp insertion and the exon 12 
G + C splice site mutation by hybridization with allele 
specific oligonucleotides (Fig. 6). A positive signal was 
obtained for the insertion mutation probe in the amplified 
DNA from the father. 
4. Discussion 
The G + C mutation in the 5’ splice site of intron 7 of 
P-hexosaminidase a-subunit gene was identified in two 
unrelated Portuguese patients, one being homozygous and 
the other a compound heterozygote with the 4 bp insertion 
within exon 11. Since the first GT at the 5’ donor site of 
introns are known to be obligatory [24], the transversion is 
expected to result in splicing failure at the junction due to 
the decrease of the donor site efficiency. Our data indicate 
that the junctional mutation indeed results in defective 
splicing of the transcripts. By Northern analysis of total 
RNA present in fibroblasts from the homozygous patient, 
the Phexosaminidase (Y mRNA was observed as a nearly 
undetectable fast migrating band. Through amplification of 
(Y chain transcripts by RT-PCR several fragments of 
smaller size than the normal transcipt hybridized with 
full-length (Y cDNA. The high percentage of abnormal 
spliced molecules might result from an altered balance 
between normal spliced molecules and those resulting 
from alternative splicing. Moreover, the smaller fragments 
are expected to be over-represented after amplification, 
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Fig. 6. Analysis of the two infantile Ashkenazi Jewish Tay-Sachs alleles. 
The region of genomic DNA encompassing both exon 11 4-bp insertion 
and intron 12 splice site was amplified by PCR and the products blotted 
onto duplicate in hybridization membranes. The samples were hybridized 
with allele-specific oligonucleotides probes to detect either the mutated or 
the corresponding normal sequences. A, 4-base insertion; B, splicing 
defect; N, normal probe; M, mutant probe; lane 1, control; lane 2, patient 
2’s father; lane 3, patient 2’s mother. 
with respect to longer fragments. The mRNA quantifica- 
tion by cDNA-PCR is only possible in the exponential 
phase of amplification, generally before the 20ti cycle of 
amplification, and at 35”’ cycle the amount of amplified 
material should depend poorly on the initial amount of 
material to be amplified. Therefore, the data should only 
be considered as qualitative and not quantitative. The 
longest fragment observed in homozygous patient fibro- 
blasts was identified as corresponding to (Y mRNA lacking 
exon 7. The skip of the exon immediately preceding a 
mutation at the 5’ donor site has been reported in the 
Ashkenazi intron 12 splicing mutation [5]. Further studies 
will be needed to evaluate if the transcripts lacking other 
segments beside exon 7 might result from the presence of 
another Tay-Sachs disease mutation or from normally oc- 
curring miss-splicing [5], although they were not detected 
in control normal fibroblasts studied. 
The sequence of mRNAs lacking just exon 7 is in frame 
and it would encode a protein shortened of 43 amino acids 
(those encoded by exon 7). However, the labeled mutated 
(Y subunit was undetectable in fibroblasts from homozy- 
gous patient. We do know from the Northern blotting 
result that the (Y subunit mRNA is nearly undetectable. 
The lack of immunological detectable (Y subunit, there- 
fore, is most likely due to instability of the abnormally 
spliced mRNA and not due to a mutant protein immuno- 
logically unrecognizable by the antiserum raised against 
the normal enzyme protein. The presence of the mutation 
G --) C in 5’ splice site of intron 7 in heterozygosity with 
the exon 11 4-bp insertion (mRNA negative) is also ex- 
pected to result in a functional abnormality. 
Another mutation at + 1 position of intron 7, the G -+ A 
transition, has been previously reported [25] in three unre- 
lated families of French-Canadian origin. The patients 
were heterozygous for this mutation, carrying in the other 
allele the 7.6 kb deletion at 5’ end of (Y chain gene. The 
effect of G + A mutation on mRNA expression was evalu- 
ated by RT-PCR. In contrast to G + C transversion, this 
mutation appears to result in the absence of LY mRNA 
since the RT-PCR procedure should have yielded reason- 
able quantities of an amplified segment even when the 
mRNA is unstable and rapidly degraded. 
Both mutations at + 1 position of intron 7 abolishe the 
restriction sites for the enzymes EcoRII and Scr FI, usu- 
ally used in the diagnosis of adult Tay-Sachs disease 
mutation. However the G + C transversion crates an AluI 
restriction site which specifically allows the detection of 
this mutation. Therefore, the G + C transversion can be 
easily and quickly screened with a restriction assay with 
AluI endonuclease, whereas unambiguous diagnosis of 
G -+ A transition requires allele-specific oligonucleotide 
hybridization. 
The absence of G -+ C mutation at + 1 position of 
intron 7 and the infantile Ashkenazi Jewish alleles in other 
two patients with Tay-Sachs disease indicates that other 
disease causing mutation(s) are present in Portuguese pop- 
ulation (data not shown). Interesting is the abstract of 
another group [26] which reported the presence of the 
intron 7 splicing mutation in heterozygosity with the 
Ashkenazi 4 bp insertion in a patient of Portuguese origin. 
Anyway, the frequency of any of these mutations in Por- 
tugese population must be quite low, as the occurrence of 
Tay-Sachs disease is rare. However, it is useful1 to know 
the molecular defect underlaying the Tay-Sachs disease in 
the families at risk since the use of the DNA-based test in 
addition to the diagnostic tests currently used to detect the 
carriers allow a more accurately definition of the carrier 
state. 
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